Citation Impact
Citing Papers
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
2008 Standout
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney
2006 StandoutNobel
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 Standout
Hepatocellular carcinoma
2018 Standout
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
2004 Standout
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
2012
ACE Inhibitors to Prevent End-Stage Renal Disease
2001
Acute Kidney Injury and Chronic Kidney Disease as Interconnected Syndromes
2014 Standout
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
2001 Standout
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
2003 Standout
Renal-Artery Stenosis
2001 Standout
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
2016
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
2001 Standout
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
2009 Standout
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
2006
Dialysis delayed is death prevented: A clinical perspective on the RENAAL study
2003
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
2016
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
2006 Standout
A New Equation to Estimate Glomerular Filtration Rate
2009 Standout
Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C
2012 Standout
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial
2005
Chronic Renal Failure after Transplantation of a Nonrenal Organ
2003 Standout
Stroke
2008 Standout
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
2003 Standout
Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
2002 Standout
Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system
2005 StandoutNobel
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
1999
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Diuretic Therapy, the α-Adducin Gene Variant, and the Risk of Myocardial Infarction or Stroke in Persons With Treated Hypertension
2002
Nephropathy in Patients with Type 2 Diabetes
2002
Chronic kidney disease: global dimension and perspectives
2013 Standout
Detection of Chronic Kidney Disease With Laboratory Reporting of Estimated Glomerular Filtration Rate and an Educational Program
2004
Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
2001
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study
2003
Inflammation in atherosclerosis
2002 StandoutNature
Population based screening for chronic kidney disease: cost effectiveness study
2010
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
2004 Standout
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
2017
How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma
2014
The Hallmarks of Aging
2013 Standout
Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
2001
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
2015 Standout
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
2004 Standout
Chronic Kidney Disease
2016 Standout
Hepatocellular carcinoma
2022 Standout
Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy
2002
Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease<SUBTITLE>Results From the AASK Trial</SUBTITLE>
2002 Standout
Hepatocellular Carcinoma
2019 Standout
Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial
2001
Effect of Telmisartan on Renal Outcomes
2009
Preserving renal function in adults with hypertension and diabetes: A consensus approach
2000
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
2002 Standout
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
2001 Standout
Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
2001 Standout
Aldosterone as a Mediator of Progressive Renal Dysfunction: Evolving Perspectives.
2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
2002
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease
2011
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease
2006
Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
2008 Standout
Renal Dysfunction Complicating the Treatment of Hypertension
2002
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
2000 Standout
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
2013 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes
2003 Standout
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
2003 Standout
Dapagliflozin in Patients with Chronic Kidney Disease
2020 Standout
Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients
2000 Standout
Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system
2005 StandoutNobel
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
2002 Standout
Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
2000
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
2002 Standout
Works of Roberto Benini being referenced
In Chronic Nephropathies Prolonged ACE Inhibition Can Induce Remission
1999
Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial
1998
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer
2013
Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies
2001
Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury
2000
ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1
2000
Chronic Proteinuric Nephropathies. II. Outcomes and Response to Treatment in a Prospective Cohort of 352 Patients
2000
Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).
1998